Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012
--Initiation of registration study for ME-401 in patients with relapsed or refractory follicular lymphoma expected before year-end--
|
Jun 4, 2018 -- 90% Objective Response Rate Observed in Patients with Indolent B-Cell Malignancies --
|
Jun 4, 2018 -- ME-344 Mitochondrial Inhibitor in Combination with Avastin Demonstrates Inhibition of Tumor Proliferation in HER2 Negative Breast Cancer Patients --
|
May 31, 2018 -- Predefined Patient Retention Threshold Met: 10% Early Discontinuation Rate Due to Adverse Events Supports Expansion of Patient Enrollment --
|
May 9, 2018 Data readouts in three programs expected in the second calendar quarter of 2018
|
Feb 13, 2018 Interim data further support potential of ME-344 to reverse resistance to antiangiogenic therapy
|
Feb 8, 2018 Pipeline advancement continues, including clearance of voruciclib IND by FDA and pracinostat Orphan Drug Designation by EMA
|
Dec 21, 2017 New Preclinical Studies Demonstrate Repression of MCL-1 and Sensitization to BCL-2 Inhibition in Diffuse Large B-Cell Lymphoma
|
